Literature DB >> 15512873

ALS trial design: expectation and reality.

Robert G Miller1, Dan H Moore.   

Abstract

Entities:  

Mesh：

Year:  2004        PMID： 15512873     DOI： 10.1080/17434470410019979

Source DB:  PubMed          Journal:  Amyotroph Lateral Scler Other Motor Neuron Disord        ISSN： 1466-0822


× No keyword cloud information.
  3 in total

1.  Progression in ALS is not linear but is curvilinear.

Authors:  Paul H Gordon; Bin Cheng; Francois Salachas; Pierre-Francois Pradat; Gaelle Bruneteau; Philippe Corcia; Lucette Lacomblez; Vincent Meininger
Journal:  J Neurol       Date:  2010-06-08       Impact factor: 4.849

2.  Comparing methods to combine functional loss and mortality in clinical trials for amyotrophic lateral sclerosis.

Authors:  Leonard H van den Berg; Stavros Nikolakopoulos; Ruben Pa van Eijk; Marinus Jc Eijkemans; Dimitris Rizopoulos
Journal:  Clin Epidemiol       Date:  2018-03-19       Impact factor: 4.790

3.  Critical design considerations for time-to-event endpoints in amyotrophic lateral sclerosis clinical trials.

Authors:  Ruben P A van Eijk; Stavros Nikolakopoulos; Kit C B Roes; Bas M Middelkoop; Toby A Ferguson; Pamela J Shaw; P Nigel Leigh; Ammar Al-Chalabi; Marinus J C Eijkemans; Leonard H van den Berg
Journal:  J Neurol Neurosurg Psychiatry       Date:  2019-07-10       Impact factor: 10.154
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.